Breakdown | TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 121.58M | 126.08M | 132.58M | 99.95M | 105.14M | 94.86M |
Gross Profit | 88.33M | 93.05M | 61.02M | 29.00M | 41.23M | 29.36M |
EBITDA | -5.79M | 4.73M | 15.15M | -12.22M | 12.17M | 5.94M |
Net Income | -19.86M | -11.54M | -1.54M | -27.27M | 4.24M | 1.12M |
Balance Sheet | ||||||
Total Assets | 163.21M | 178.56M | 185.73M | 158.36M | 194.59M | 168.76M |
Cash, Cash Equivalents and Short-Term Investments | 31.15M | 40.11M | 45.35M | 19.00M | 38.87M | 61.10M |
Total Debt | 0.00 | 33.24M | 29.41M | 13.84M | 10.00M | 436.00K |
Total Liabilities | 52.97M | 59.66M | 65.82M | 49.97M | 54.51M | 37.71M |
Stockholders Equity | 110.25M | 118.90M | 119.91M | 108.39M | 140.09M | 131.06M |
Cash Flow | ||||||
Free Cash Flow | -7.44M | -3.24M | 7.60M | -20.59M | 9.11M | 10.34M |
Operating Cash Flow | -5.32M | 248.00K | 10.51M | -17.22M | 15.39M | 14.01M |
Investing Cash Flow | 4.15M | -2.94M | -6.82M | 6.23M | -25.24M | -9.07M |
Financing Cash Flow | -2.65M | -2.95M | 18.41M | -375.00K | 10.23M | -4.65M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $361.88M | ― | -7.46% | ― | -3.31% | -199.23% | |
60 Neutral | HK$15.31B | 5.72 | -7.43% | 4.61% | 11.60% | -21.06% | |
59 Neutral | $319.11M | ― | -76.21% | ― | 23.22% | 9.54% | |
49 Neutral | $414.68M | ― | -16.96% | ― | -14.96% | -245.49% | |
48 Neutral | $369.60M | ― | -161.19% | ― | 1.64% | 16.02% | |
47 Neutral | $447.13M | ― | -177.29% | ― | -23.99% | -100.40% | |
41 Neutral | $383.09M | ― | -45.73% | ― | 7.54% | 4.28% |
On June 5, 2025, Surmodics, Inc. experienced a cyber incident where a threat actor gained unauthorized access to its IT systems, rendering some data and systems temporarily unavailable. The company promptly initiated containment measures, worked with third-party IT experts, and restored critical IT systems, ensuring customer orders and shipments continued without significant disruption. The company is still analyzing the scope of the data accessed but has not found evidence of data misuse. Surmodics expects its cyber insurance to cover most related expenditures, though it remains exposed to risks such as management distraction, potential litigation, and regulatory scrutiny.
The most recent analyst rating on (SRDX) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on SurModics stock, see the SRDX Stock Forecast page.